Northwest Biotherapeutics is developing two drug platforms -- DCVax and HuRx -- based on monoclonal antibodies. The company's patented monoclonal antibodies are designed to attach to cancer-causing antigens and kill cancer cells in cancers ranging from prostate and brain cancer to skin and breast cancer.